Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells.
about
Development of Novel Immunotherapies for Multiple MyelomaExtracellular Matrix, a Hard Player in AngiogenesisMicroRNA-330-3p promotes cell invasion and metastasis in non-small cell lung cancer through GRIA3 by activating MAPK/ERK signaling pathway.The involvement of proteoglycans in the human plasma prekallikrein interaction with the cell surface.Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow.Low Soluble Syndecan-1 Precedes Preeclampsia.Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenograftsHeparanase-induced shedding of syndecan-1/CD138 in myeloma and endothelial cells activates VEGFR2 and an invasive phenotype: prevention by novel synstatins.Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions.Monoclonal antibody-based immunotherapy for multiple myeloma.Targeting syndecans: a promising strategy for the treatment of cancer.Syndecans as modulators and potential pharmacological targets in cancer progression.The prospects and promise of chimeric antigen receptor immunotherapy in multiple myeloma.Insights into the molecular roles of heparan sulfate proteoglycans (HSPGs-syndecans) in autocrine and paracrine growth factor signaling in the pathogenesis of Hodgkin's lymphoma.Loss of cell invasiveness through PKC-mediated syndecan-1 downregulation in melanoma cells under anchorage independency.Endothelial glycocalyx as a critical signalling platform integrating the extracellular haemodynamic forces and chemical signalling.Syndecan-1 increases B-lymphoid cell extravasation in response to HIV-1 Tat via αvβ3/pp60src/pp125FAK pathway.Chemotherapy stimulates syndecan-1 shedding: a potentially negative effect of treatment that may promote tumor relapsepiRNA-823 contributes to tumorigenesis by regulating de novo DNA methylation and angiogenesis in multiple myeloma.Cancer Cell Glycocalyx and Its Significance in Cancer ProgressionHeparan Sulfate and Heparan Sulfate Proteoglycans in Cancer Initiation and Progression
P2860
Q28066890-2651FA63-4D49-472D-BC57-D47D9193B3F5Q28072886-D7B357FD-86DD-4415-95E4-C75086B4A1BAQ33814564-738FD64C-51B5-48B8-9827-B6B5451D6F5DQ35118601-9B9A866A-0A85-419B-A064-F065E616FFD7Q35834665-C32918DD-B7B5-448C-A4B7-4D4AF357F82CQ36051671-BB724C33-D046-4AE9-961B-AA8F7BBF2499Q36545764-61D68AD9-5A56-4241-B51A-4EDCD73EF8DDQ37499263-4B1EE7F7-AB83-418A-959B-BB6936238686Q38014834-16B1AFEA-4E8C-4DBB-A79E-A91794D2FDE8Q38050507-901A7587-0E54-4B45-80B1-FD9E6233BAFDQ38082795-97A9D62E-EC81-4F94-AC61-91FD986E0EEEQ38189392-A718BC66-2673-441B-B298-186B81B9043DQ38764944-BD44CB6C-36FD-45CB-B556-94FC4D58B461Q38868904-3E4C7F63-6B6B-4820-B560-9739A20ED657Q38955166-167B3293-4408-4452-8EA2-01E92C26722CQ39140372-F357204F-0C61-4623-A5C1-DE0B648BA18EQ40486626-8C4259BC-5B97-4196-BCD8-AB757A0170A7Q42021140-A4091141-42D7-46E6-B290-80A63D392E9EQ53239319-0D5209B9-B6A9-401A-82CC-0BEBBEDBB2F0Q57168005-D847E813-BAD0-4AD5-8D43-EEF6D3C3A80CQ58705289-62E101B9-91C0-4473-95CC-BCAD79C94900
P2860
Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells.
@en
Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells.
@nl
type
label
Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells.
@en
Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells.
@nl
prefLabel
Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells.
@en
Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells.
@nl
P2093
P2860
P50
P356
P1433
P1476
Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells
@en
P2093
P2860
P2888
P304
P356
10.1038/LEU.2011.290
P577
2011-10-25T00:00:00Z
P5875
P6179
1011333516